nitrazepam 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
diazepam derivatives	1945	146-22-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: nitrazadon nitrazepam neozepam nitrodiazepam	A benzodiazepine derivative used as an anticonvulsant and hypnotic. Molecular weight: 281.27 Formula: C15H11N3O3 CLOGP: 2.32 LIPINSKI: 0 HAC: 6 HDO: 1 TPSA: 87.28 ALOGS: -3.97 ROTB: 2

Molecule

Description

Molfile Inchi Smiles

Synonyms:

nitrazadon
nitrazepam
neozepam
nitrodiazepam

A benzodiazepine derivative used as an anticonvulsant and hypnotic.

Molecular weight: 281.27
Formula: C15H11N3O3
CLOGP: 2.32
LIPINSKI: 0
HAC: 6
HDO: 1
TPSA: 87.28
ALOGS: -3.97
ROTB: 2

Drug dosage:

Dose	Unit	Route
5	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.03 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0.50 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	1.02 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	78 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	1.70 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	0.86 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.13 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	26 hours	Lombardo F, Berellini G, Obach RS

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Enthesopathy	360.05	28.99	103	8125	7090	50589806
Tenosynovitis	320.99	28.99	103	8125	10462	50586434
Blood parathyroid hormone decreased	316.67	28.99	93	8135	7021	50589875
Tongue disorder	305.40	28.99	96	8132	9120	50587776
Panniculitis	300.30	28.99	93	8135	8410	50588486
Red blood cell sedimentation rate	280.49	28.99	73	8155	3513	50593383
Skin necrosis	277.87	28.99	93	8135	10774	50586122
Granuloma skin	271.89	28.99	79	8149	5739	50591157
Rheumatoid nodule	263.42	28.99	93	8135	12642	50584254
Tendonitis	242.37	28.99	94	8134	16611	50580285
Ulcer	221.71	28.99	93	8135	20107	50576789
Drug eruption	217.42	28.99	96	8132	23510	50573386
Hypercalcaemia	211.95	28.99	94	8134	23258	50573638
Basal cell carcinoma	205.52	28.99	92	8136	23264	50573632
C-reactive protein abnormal	196.25	28.99	94	8134	27715	50569181
Skin ulcer	174.99	28.99	94	8134	35224	50561672
Alanine aminotransferase abnormal	170.34	28.99	51	8177	4105	50592791
Red blood cell sedimentation rate increased	156.17	28.99	82	8146	29334	50567562
Psoriatic arthropathy	149.95	28.99	94	8134	46938	50549958
Fear of injection	147.13	28.99	50	8178	6053	50590843
Rash pruritic	143.48	28.99	92	8136	47754	50549142
Inflammation	133.61	28.99	94	8134	56818	50540078
Aspartate aminotransferase increased	125.92	28.99	103	8125	77895	50519001
Loss of personal independence in daily activities	124.77	28.99	98	8130	69952	50526944
Alanine aminotransferase increased	114.74	28.99	103	8125	88256	50508640
C-reactive protein increased	95.28	28.99	82	8146	66392	50530504
Drug tolerance decreased	86.66	28.99	38	8190	9122	50587774
Joint injury	86.03	28.99	50	8178	21739	50575157
Synovitis	80.78	28.99	100	8128	123765	50473131
Blood pressure systolic increased	77.25	28.99	56	8172	35393	50561503
Chest discomfort	75.65	28.99	84	8144	92638	50504258
Therapy non-responder	69.17	28.99	61	8167	50961	50545935
Erythema	66.25	28.99	99	8129	146315	50450581
Granuloma	62.20	28.99	25	8203	4833	50592063
Suicide attempt	53.09	28.99	53	8175	51679	50545217
Drug tolerance	51.50	28.99	22	8206	4954	50591942
Infusion related reaction	45.49	28.99	91	8137	169466	50427430
Retinal vein occlusion	39.85	28.99	14	8214	1867	50595029
Rheumatoid arthritis	38.81	28.99	95	8133	202455	50394441
Intellectual disability	38.03	28.99	11	8217	783	50596113
Peripheral swelling	37.78	28.99	95	8133	205841	50391055
Product use issue	37.44	28.99	78	8150	149397	50447499
Rheumatoid lung	36.16	28.99	14	8214	2451	50594445
Blood creatinine increased	35.09	28.99	52	8176	76108	50520788
Drug intolerance	34.02	28.99	95	8133	219009	50377887
Drug hypersensitivity	33.40	28.99	103	8125	250907	50345989
Pain in extremity	33.39	28.99	3	8225	272862	50324034
Angioplasty	33.07	28.99	11	8217	1244	50595652
Musculoskeletal disorder	32.40	28.99	25	8203	17324	50579572
Musculoskeletal stiffness	32.10	28.99	67	8161	128414	50468482
Contraindicated product administered	29.72	28.99	71	8157	148887	50448009
Limb injury	29.00	28.99	25	8203	20225	50576671

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Tenosynovitis	275.84	25.03	73	4867	3660	29565927
Enthesopathy	275.65	25.03	73	4867	3670	29565917
Tongue disorder	233.07	25.03	67	4873	4569	29565018
C-reactive protein abnormal	218.66	25.03	69	4871	6467	29563120
Synovitis	198.86	25.03	73	4867	10817	29558770
Alanine aminotransferase abnormal	177.00	25.03	49	4891	2908	29566679
Tendonitis	162.63	25.03	58	4882	7903	29561684
Psoriatic arthropathy	128.21	25.03	58	4882	14633	29554954
Loss of personal independence in daily activities	125.21	25.03	68	4872	25372	29544215
Treatment failure	111.51	25.03	72	4868	36867	29532720
Drug hypersensitivity	93.53	25.03	83	4857	68323	29501264
Aspartate aminotransferase increased	92.86	25.03	78	4862	59647	29509940
Drug intolerance	78.93	25.03	65	4875	48314	29521273
Erythema	73.44	25.03	76	4864	75530	29494057
Alanine aminotransferase increased	70.13	25.03	72	4868	70872	29498715
Red blood cell sedimentation rate	51.40	25.03	13	4927	541	29569046
Granuloma skin	49.37	25.03	13	4927	635	29568952
Suicide attempt	47.73	25.03	42	4898	34068	29535519
Intentional overdose	47.16	25.03	44	4896	38484	29531103
Contraindicated product administered	46.34	25.03	32	4908	18234	29551353
Blood parathyroid hormone decreased	46.28	25.03	13	4927	811	29568776
Neuroleptic malignant syndrome	42.64	25.03	29	4911	16119	29553468
Panniculitis	41.23	25.03	13	4927	1208	29568379
Cor pulmonale acute	40	25.03	9	4931	225	29569362
Headache	38.91	25.03	88	4852	173919	29395668
Altered state of consciousness	37.22	25.03	29	4911	19860	29549727
C-reactive protein increased	35.03	25.03	40	4900	44223	29525364
Rheumatoid nodule	34.20	25.03	13	4927	2109	29567478
Procedural failure	31.21	25.03	6	4934	67	29569520
Hypersensitivity	30.86	25.03	41	4899	52862	29516725
Dystonia	26.91	25.03	18	4922	9731	29559856
Multiple-drug resistance	26.58	25.03	13	4927	3887	29565700
Compartment syndrome	25.62	25.03	11	4929	2441	29567146
Rhabdomyolysis	25.08	25.03	40	4900	60768	29508819

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Enthesopathy	548.92	22.72	159	12464	9479	64476630
Tenosynovitis	516.73	22.72	159	12464	11674	64474435
Tongue disorder	463.31	22.72	147	12476	11933	64474176
Tendonitis	363.53	22.72	140	12483	20142	64465967
C-reactive protein abnormal	337.62	22.72	147	12476	28900	64457209
Alanine aminotransferase abnormal	332.39	22.72	100	12523	6788	64479321
Blood parathyroid hormone decreased	304.66	22.72	95	12528	7271	64478838
Panniculitis	287.21	22.72	95	12528	8784	64477325
Red blood cell sedimentation rate	278.33	22.72	76	12547	3638	64482471
Granuloma skin	262.39	22.72	81	12542	5993	64480116
Psoriatic arthropathy	261.87	22.72	140	12483	43141	64442968
Rheumatoid nodule	254.31	22.72	95	12528	12556	64473553
Skin necrosis	242.80	22.72	95	12528	14234	64471875
Loss of personal independence in daily activities	216.37	22.72	149	12474	72305	64413804
Ulcer	202.63	22.72	96	12527	22894	64463215
Synovitis	189.39	22.72	156	12467	98934	64387175
Drug eruption	180.33	22.72	103	12520	36033	64450076
Aspartate aminotransferase increased	179.25	22.72	164	12459	119624	64366485
Hypercalcaemia	174.29	22.72	96	12527	31320	64454789
Basal cell carcinoma	173.19	22.72	95	12528	30743	64455366
Alanine aminotransferase increased	147.82	22.72	158	12465	138873	64347236
Skin ulcer	146.87	22.72	97	12526	43877	64442232
Fear of injection	143.34	22.72	51	12572	5861	64480248
Rash pruritic	117.19	22.72	94	12529	57310	64428799
Inflammation	112.67	22.72	97	12526	65203	64420906
Red blood cell sedimentation rate increased	111.86	22.72	72	12551	31163	64454946
Erythema	111.71	22.72	159	12464	186911	64299198
C-reactive protein increased	104.56	22.72	110	12513	94799	64391310
Treatment failure	102.20	22.72	120	12503	116696	64369413
Drug intolerance	95.29	22.72	148	12475	187844	64298265
Drug hypersensitivity	93.49	22.72	167	12456	237648	64248461
Therapy non-responder	88.38	22.72	85	12538	65814	64420295
Joint injury	77.50	22.72	51	12572	22896	64463213
Contraindicated product administered	64.76	22.72	92	12531	107737	64378372
Drug tolerance decreased	57.89	22.72	28	12595	6970	64479139
Blood pressure systolic increased	57.43	22.72	59	12564	49394	64436715
Granuloma	53.22	22.72	26	12597	6615	64479494
Chest discomfort	52.69	22.72	87	12536	116019	64370090
Suicide attempt	47.74	22.72	64	12559	70943	64415166
Drug tolerance	46.31	22.72	23	12600	6062	64480047
Rheumatoid arthritis	43.54	22.72	98	12525	164196	64321913
Infusion related reaction	39.08	22.72	94	12529	164373	64321736
Neuroleptic malignant syndrome	38.80	22.72	35	12588	24961	64461148
Asthenia	38.27	22.72	18	12605	428026	64058083
Dyspnoea	38.24	22.72	51	12572	718623	63767486
Rheumatoid lung	36.96	22.72	15	12608	2464	64483645
Pain in extremity	35.39	22.72	8	12615	303077	64183032
Angioplasty	35.10	22.72	13	12610	1672	64484437
Salivary hypersecretion	33.95	22.72	24	12599	12089	64474020
Altered state of consciousness	33.19	22.72	39	12584	37863	64448246
Limb injury	32.77	22.72	31	12592	23474	64462635
Intentional overdose	32.49	22.72	61	12562	89883	64396226
Musculoskeletal stiffness	32.07	22.72	73	12550	123133	64362976
Peripheral swelling	31.30	22.72	101	12522	209052	64277057
Retinal vein occlusion	31.05	22.72	14	12609	2974	64483135
Cor pulmonale acute	29.85	22.72	9	12614	613	64485496
Musculoskeletal disorder	29.63	22.72	26	12597	17880	64468229
Procedural failure	29.28	22.72	6	12617	80	64486029
Psychiatric symptom	28.92	22.72	17	12606	6256	64479853
Back pain	28.42	22.72	7	12616	250164	64235945
Pneumonia aspiration	27.65	22.72	45	12578	59226	64426883
Product dose omission issue	27.54	22.72	3	12620	194744	64291365
Headache	26.12	22.72	185	12438	529282	63956827
Arthritis	25.62	22.72	53	12570	83761	64402348
Product use issue	25.21	22.72	76	12547	151639	64334470
Dystonia	24.63	22.72	24	12599	18841	64467268
Multiple-drug resistance	23.29	22.72	15	12608	6487	64479622
Choking	23.07	22.72	18	12605	10520	64475589

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N05CD02	NERVOUS SYSTEM PSYCHOLEPTICS HYPNOTICS AND SEDATIVES Benzodiazepine derivatives
MeSH PA	D014151	Anti-Anxiety Agents
MeSH PA	D000927	Anticonvulsants
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D002492	Central Nervous System Depressants
MeSH PA	D018682	GABA Agents
MeSH PA	D018757	GABA Modulators
MeSH PA	D006993	Hypnotics and Sedatives
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D011619	Psychotropic Drugs
MeSH PA	D014149	Tranquilizing Agents
CHEBI has role	CHEBI:35623	anticonvulsants
CHEBI has role	CHEBI:35717	hypnotics
CHEBI has role	CHEBI:49103	drug metabolites
CHEBI has role	CHEBI:50268	GABA modulators
CHEBI has role	CHEBI:53784	antispasmodics

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Myoclonic seizure	indication	37356005
Insomnia	indication	193462001

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	11.11	acidic
pKa2	2.85	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
GABA-A receptor alpha-1/beta-2/gamma-2	Ion channel	P14867 P18507 P47870	GBRA1_HUMAN GBRG2_HUMAN GBRB2_HUMAN	POSITIVE ALLOSTERIC MODULATOR	EC50	8		WOMBAT-PK	KEGG DRUG
GABA-A receptor; anion channel	Ion channel		GBRA1_BOVIN GBRB1_BOVIN GBRA2_BOVIN GBRA3_BOVIN GBRA4_BOVIN GBRG2_BOVIN		IC50	7.42		CHEMBL

External reference:

ID	Source
N0000166923	NUI
D00531	KEGG_DRUG
C0028126	UMLSCUI
CHEBI:7581	CHEBI
CHEMBL13209	ChEMBL_ID
DB01595	DRUGBANK_ID
D009567	MESH_DESCRIPTOR_UI
4506	PUBCHEM_CID
2121	INN_ID
9CLV70W7HS	UNII
152070	RXNORM
003484	NDDF
387449001	SNOMEDCT_US
78449007	SNOMEDCT_US

Pharmaceutical products:

None